CY1110149T1 - SPECIAL COMPONENT OF GLUCCORDOSTEROID WITH ANTI-INFLAMMATIVE ACTIVITY - Google Patents
SPECIAL COMPONENT OF GLUCCORDOSTEROID WITH ANTI-INFLAMMATIVE ACTIVITYInfo
- Publication number
- CY1110149T1 CY1110149T1 CY20101100601T CY101100601T CY1110149T1 CY 1110149 T1 CY1110149 T1 CY 1110149T1 CY 20101100601 T CY20101100601 T CY 20101100601T CY 101100601 T CY101100601 T CY 101100601T CY 1110149 T1 CY1110149 T1 CY 1110149T1
- Authority
- CY
- Cyprus
- Prior art keywords
- gluccordosteroid
- inflammative
- activity
- special component
- special
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
Abstract
Ένωση τύπου (Ι) ή φυσιολογικώς αποδεκτό διαλύτωμα αυτής.A compound of formula (I) or a physiologically acceptable solvate thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0316290.6A GB0316290D0 (en) | 2003-07-11 | 2003-07-11 | Novel compounds |
EP04741020A EP1644397B1 (en) | 2003-07-11 | 2004-07-09 | Specific glucocorticosteroid compound having anti- inflammatory activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110149T1 true CY1110149T1 (en) | 2015-01-14 |
Family
ID=27742019
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100601T CY1110149T1 (en) | 2003-07-11 | 2010-06-30 | SPECIAL COMPONENT OF GLUCCORDOSTEROID WITH ANTI-INFLAMMATIVE ACTIVITY |
CY20131100230T CY1113836T1 (en) | 2003-07-11 | 2013-03-19 | SPECIAL GLYCORDIC STEROID UNION WITH ANTI-INFLAMMATORY ACTION |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100230T CY1113836T1 (en) | 2003-07-11 | 2013-03-19 | SPECIAL GLYCORDIC STEROID UNION WITH ANTI-INFLAMMATORY ACTION |
Country Status (31)
Country | Link |
---|---|
US (6) | US7291609B2 (en) |
EP (3) | EP2380898B1 (en) |
JP (3) | JP4709752B2 (en) |
KR (2) | KR101029207B1 (en) |
CN (3) | CN1845933B (en) |
AR (2) | AR045901A1 (en) |
AT (1) | ATE467638T1 (en) |
AU (2) | AU2004255855B2 (en) |
BR (2) | BRPI0412527A (en) |
CA (2) | CA2531905C (en) |
CY (2) | CY1110149T1 (en) |
DE (1) | DE602004027137D1 (en) |
DK (2) | DK1644398T3 (en) |
ES (3) | ES2433665T3 (en) |
GB (1) | GB0316290D0 (en) |
HK (2) | HK1089186A1 (en) |
HR (2) | HRP20100359T1 (en) |
IL (3) | IL172776A (en) |
IS (3) | IS2776B (en) |
MA (2) | MA27897A1 (en) |
MX (2) | MXPA06000443A (en) |
MY (2) | MY140987A (en) |
NO (2) | NO333263B1 (en) |
NZ (2) | NZ544576A (en) |
PL (2) | PL1644398T3 (en) |
PT (2) | PT1644398E (en) |
RU (3) | RU2348645C2 (en) |
SI (2) | SI1644398T1 (en) |
TW (2) | TWI338694B (en) |
WO (2) | WO2005005452A1 (en) |
ZA (2) | ZA200600226B (en) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
DE102004025985A1 (en) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estriol and estetrol prodrugs |
DE102004025966A1 (en) * | 2004-05-21 | 2005-12-15 | Schering Ag | Estradiol prodrugs |
WO2006072599A2 (en) * | 2005-01-10 | 2006-07-13 | Glaxo Group Limited | Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
US20090124588A1 (en) * | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
EP2484382A1 (en) * | 2005-03-30 | 2012-08-08 | Schering Corporation | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form |
AU2006270165B2 (en) | 2005-07-14 | 2010-03-11 | Neothetics, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
TW200811111A (en) | 2006-04-20 | 2008-03-01 | Glaxo Group Ltd | Novel compounds |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
PL2077830T3 (en) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Methods, compositions, and formulations for the treatment of thyroid eye disease |
PE20081889A1 (en) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | INDOL CARBOXAMIDES AS INHIBITORS OF IKK2 |
CN102137858B (en) | 2008-05-23 | 2014-07-23 | 潘米拉制药有限责任公司 | 5-lipoxygenase-activating protein inhibitor |
JP5502858B2 (en) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 4-Carboxamide indazole derivatives useful as inhibitors of PI3 kinase |
WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
ES2542551T3 (en) | 2009-03-09 | 2015-08-06 | Glaxo Group Limited | 4-Oxadiazol-2-yl-indazoles as inhibitors of PI3 kinases |
US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
JP2012520845A (en) | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Pyrimidine derivatives used as Itk inhibitors |
BRPI1009271A8 (en) | 2009-03-19 | 2016-02-10 | Merck Sharp & Dohme | DOUBLE-STRAND SHORT INTERFERING NUCLEIC ACID MOLECULE, PHARMACEUTICAL COMPOSITION, AND, METHOD FOR TREATMENT A HUMAN INDIVIDUAL SUFFERING FROM A CONDITION THAT IS MEDIATED BY THE ACTION, OR LOSS OF ACTION, OF BACH1 |
US20120016011A1 (en) | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
JP2012520686A (en) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | RNA interference-mediated inhibition of signal transduction transcription factor 6 (STAT6) gene expression using small interfering nucleic acids (siNA) |
WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2411520A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
JP2012521760A (en) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | RNA interference-mediated inhibition of apoptosis signal-regulated kinase 1 (ASK1) gene expression using small interfering nucleic acids (siNA) |
WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2411018A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
CN102439152A (en) | 2009-03-27 | 2012-05-02 | 默沙东公司 | Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1)gene expression using short interfering nucleic acid (sina) |
US8399436B2 (en) | 2009-04-24 | 2013-03-19 | Glaxo Group Limited | N-pyrazolyl carboxamides as CRAC channel inhibitors |
EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
MY160454A (en) | 2009-04-30 | 2017-03-15 | Glaxo Group Ltd | Oxazole substituted indazoles as pi3-kinase inhibitors |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
MX2011012669A (en) | 2009-05-29 | 2011-12-16 | Pfizer Ltd | Novel glucocorticoid receptor agonists. |
WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
JP2013512879A (en) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Benzpyrazole derivatives as inhibitors of PI3 kinase |
US20120238559A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Novel compounds |
EP2507231A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
GB2487868B (en) * | 2010-01-15 | 2014-12-10 | Neothetics Inc | Lyophilized cake formulations |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
PL2614058T3 (en) | 2010-09-08 | 2015-12-31 | Glaxosmithkline Ip Dev Ltd | POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE |
EP2613781B1 (en) | 2010-09-08 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Indazole derivatives for use in the treatment of influenza virus infection |
UY33597A (en) | 2010-09-09 | 2012-04-30 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
EP2630127A1 (en) | 2010-10-21 | 2013-08-28 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
WO2012052458A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
WO2012074856A2 (en) | 2010-11-24 | 2012-06-07 | Lithera, Inc. | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
PE20140378A1 (en) | 2011-02-25 | 2014-03-28 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF TRK |
WO2012123312A1 (en) | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
US10155001B2 (en) | 2013-06-14 | 2018-12-18 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | RAC1 inhibitors for inducing bronchodilation |
CA2923995A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
JP6475707B2 (en) | 2013-10-17 | 2019-02-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | PI3K inhibitors for the treatment of respiratory diseases |
SG11201609276RA (en) | 2014-05-12 | 2016-12-29 | Glaxosmithkline Ip No 2 Ltd | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US20190161480A1 (en) | 2016-08-08 | 2019-05-30 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US11759472B2 (en) * | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
MX2020005155A (en) | 2017-11-21 | 2020-08-20 | Axerovision Inc | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface. |
BR112022019245A2 (en) | 2020-03-26 | 2022-11-16 | Glaxosmithkline Ip Dev Ltd | CATHEPSIN INHIBITORS TO PREVENT OR TREAT VIRAL INFECTIONS |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3943124A (en) * | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
GB1384372A (en) * | 1971-01-20 | 1975-02-19 | Glaxo Lab Ltd | Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids |
US3686978A (en) | 1971-04-09 | 1972-08-29 | Fairfied Mfg Co Inc | Plantetary reduction wheel hub |
GB1438940A (en) * | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
US4093721A (en) * | 1974-08-30 | 1978-06-06 | Glaxo Laboratories Limited | Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof |
GB1514476A (en) * | 1974-08-30 | 1978-06-14 | Glaxo Lab Ltd | Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates |
GB2137206B (en) | 1980-02-15 | 1985-04-03 | Glaxo Group Ltd | Androstane 17-carbothioc acid derivatives |
US4996335A (en) * | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
SE449106B (en) | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | STEROID WITH ANTI-INFLAMMATORY EFFECT AND COMPOSITION CONTAINING THIS |
WO1989003390A1 (en) * | 1987-10-13 | 1989-04-20 | Bodor Nicholas S | Soft steroids having anti-inflammatory activity |
US5990099A (en) | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
SK279958B6 (en) | 1992-04-02 | 1999-06-11 | Smithkline Beecham Corporation | Compounds exhibiting anti-allergic and anti-inflammatory properties, pharmaceutical composition them containing and their use |
CA2192668A1 (en) | 1994-06-15 | 1995-12-21 | Harold Francis Hodson | Amidino sulfone derivatives for use as inos inhibitors claims |
US6172054B1 (en) * | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
WO1997041867A1 (en) | 1996-05-09 | 1997-11-13 | Alcon Laboratories, Inc. | Use of steroid compounds to prevent non-cancerous tissue growth |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
US6245804B1 (en) | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
DE19723722A1 (en) | 1997-05-30 | 1998-12-10 | Schering Ag | Nonsteroidal progestogens |
WO1999016768A1 (en) * | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzofuran derivatives |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
DE69918422T2 (en) | 1998-03-14 | 2005-08-11 | Altana Pharma Ag | Phthalazinone as PDE3 / 4 inhibitors |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
CN1353717A (en) | 1999-05-04 | 2002-06-12 | 莱加制药公司 | Tetracyclic progesterone receptor modulator compounds and methods |
ES2165768B1 (en) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
US6263209B1 (en) | 1999-07-28 | 2001-07-17 | Motorola, Inc. | Method and apparatus in a wireless communication system for creating a learning function |
CO5180649A1 (en) | 1999-09-01 | 2002-07-30 | Abbott Lab | ANTAGONISTS OF GLUCOCORTICOID RECEPTORS FOR THE TREATMENT OF DIABETES FOR THE TREATMENT OF DIABETES |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
ES2523930T3 (en) * | 2000-08-05 | 2014-12-02 | Glaxo Group Limited | 6-alpha, 9-alpha-difluoro-17-alpha - [(2-furanylcarbonyl) oxy] -11-beta-hydroxy-16-alpha-methyl-3-oxo-androst-1,4-acid s-fluoromethyl ester -dien-17-carbothioic as an anti-inflammatory agent |
AU2001290143A1 (en) | 2000-09-29 | 2002-04-08 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
EP1341541A4 (en) | 2000-11-16 | 2004-11-17 | Alcon Mfg Ltd | Combination therapy for lowering and controlling intraocular pressure |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
WO2002070490A1 (en) | 2001-03-08 | 2002-09-12 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
ES2296923T3 (en) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | FORMANILID DERIVATIVES AS AGONISTS OF THE BETA2 ADRENORRECEPTOR. |
DE60229372D1 (en) * | 2001-04-30 | 2008-11-27 | Glaxo Group Ltd | ANTIPHLOGISTIC 7.BETA.-CARBOTHIOATES ESTER DERIVATIVES OF ANDROSTAN WITH A 17.ALPHA CYCLIC ESTER GROUP |
KR20090057477A (en) | 2001-09-14 | 2009-06-05 | 글락소 그룹 리미티드 | Phenethanolamine derivatives for treatment of respiratory diseases |
GB0125259D0 (en) * | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
ATE346058T1 (en) | 2002-01-14 | 2006-12-15 | Boehringer Ingelheim Pharma | GLUCOCORTICOID MIMETICS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND USES THEREOF |
AU2003202044A1 (en) | 2002-01-15 | 2003-09-09 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
NZ535889A (en) | 2002-03-26 | 2006-03-31 | Boehringer Ingelheim Pharma | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
AU2003230700A1 (en) | 2002-03-26 | 2003-10-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (en) | 2002-04-02 | 2003-12-18 | Schering Ag | Quinoline and isoquinoline derivatives, a pharmaceutical agent and their use as anti-inflammatory agents |
US6897224B2 (en) | 2002-04-02 | 2005-05-24 | Schering Ag | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
WO2003086294A2 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
ATE381535T1 (en) | 2002-04-25 | 2008-01-15 | Glaxo Group Ltd | PHENETHANOLAMINE DERIVATIVES |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
AU2003281355A1 (en) | 2002-07-08 | 2004-01-23 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
WO2004009017A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
ES2337679T3 (en) | 2002-07-18 | 2010-04-28 | Bristol-Myers Squibb Company | COMPOSITIONS AND PROCEDURES INVOLVING SITE II OF NUCLEAR HORMONE RECEPTORS. |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
DE60322713D1 (en) | 2002-08-21 | 2008-09-18 | Boehringer Ingelheim Pharma | SUBSTITUTED DIHYDROCHINOLINS AS GLUCOCORTICOID MMIMETICS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS AND THEIR USE |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
MXPA05002887A (en) | 2002-09-16 | 2005-05-27 | Glaxo Group Ltd | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors. |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
US20050245588A1 (en) | 2002-09-20 | 2005-11-03 | Amjad Ali | Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
WO2004037807A2 (en) | 2002-10-22 | 2004-05-06 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
DE60320007T2 (en) | 2002-10-28 | 2009-06-18 | Glaxo Group Ltd., Greenford | Phenthanolamine derivatives for the treatment of respiratory diseases |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
-
2003
- 2003-07-11 GB GBGB0316290.6A patent/GB0316290D0/en not_active Ceased
-
2004
- 2004-07-08 AR ARP040102428A patent/AR045901A1/en unknown
- 2004-07-08 AR ARP040102427A patent/AR045900A1/en unknown
- 2004-07-09 AU AU2004255855A patent/AU2004255855B2/en not_active Ceased
- 2004-07-09 CN CN2004800255908A patent/CN1845933B/en not_active Expired - Fee Related
- 2004-07-09 EP EP11151276.0A patent/EP2380898B1/en active Active
- 2004-07-09 CN CN2011102290522A patent/CN102372756A/en active Pending
- 2004-07-09 MX MXPA06000443A patent/MXPA06000443A/en active IP Right Grant
- 2004-07-09 RU RU2005141064/04A patent/RU2348645C2/en active
- 2004-07-09 PL PL04763226T patent/PL1644398T3/en unknown
- 2004-07-09 WO PCT/EP2004/007820 patent/WO2005005452A1/en active Application Filing
- 2004-07-09 ES ES11151276T patent/ES2433665T3/en active Active
- 2004-07-09 SI SI200432006T patent/SI1644398T1/en unknown
- 2004-07-09 BR BRPI0412527-4A patent/BRPI0412527A/en not_active Application Discontinuation
- 2004-07-09 EP EP04741020A patent/EP1644397B1/en active Active
- 2004-07-09 MY MYPI20042746A patent/MY140987A/en unknown
- 2004-07-09 NZ NZ544576A patent/NZ544576A/en unknown
- 2004-07-09 JP JP2006518181A patent/JP4709752B2/en not_active Expired - Fee Related
- 2004-07-09 DK DK04763226.0T patent/DK1644398T3/en active
- 2004-07-09 WO PCT/EP2004/007819 patent/WO2005005451A1/en active Application Filing
- 2004-07-09 TW TW093120707A patent/TWI338694B/en not_active IP Right Cessation
- 2004-07-09 DE DE602004027137T patent/DE602004027137D1/en active Active
- 2004-07-09 JP JP2006518180A patent/JP4709751B2/en not_active Expired - Fee Related
- 2004-07-09 PT PT47632260T patent/PT1644398E/en unknown
- 2004-07-09 TW TW093120698A patent/TWI367888B/en not_active IP Right Cessation
- 2004-07-09 ES ES04741020T patent/ES2343685T3/en active Active
- 2004-07-09 PL PL04741020T patent/PL1644397T3/en unknown
- 2004-07-09 PT PT04741020T patent/PT1644397E/en unknown
- 2004-07-09 US US10/564,299 patent/US7291609B2/en active Active
- 2004-07-09 CA CA2531905A patent/CA2531905C/en not_active Expired - Fee Related
- 2004-07-09 CN CN2004800256690A patent/CN1849330B/en not_active Expired - Fee Related
- 2004-07-09 RU RU2005141226/04A patent/RU2359973C2/en active
- 2004-07-09 MX MXPA06000442A patent/MXPA06000442A/en active IP Right Grant
- 2004-07-09 NZ NZ544577A patent/NZ544577A/en unknown
- 2004-07-09 KR KR1020067000690A patent/KR101029207B1/en active IP Right Grant
- 2004-07-09 DK DK04741020.4T patent/DK1644397T3/en active
- 2004-07-09 ES ES04763226T patent/ES2400821T3/en active Active
- 2004-07-09 AU AU2004255854A patent/AU2004255854B2/en not_active Ceased
- 2004-07-09 BR BRPI0412526-6A patent/BRPI0412526A/en not_active Application Discontinuation
- 2004-07-09 CA CA2531911A patent/CA2531911C/en not_active Expired - Fee Related
- 2004-07-09 EP EP04763226A patent/EP1644398B1/en active Active
- 2004-07-09 SI SI200431471T patent/SI1644397T1/en unknown
- 2004-07-09 KR KR1020067000738A patent/KR101075324B1/en active IP Right Grant
- 2004-07-09 MY MYPI20042752A patent/MY137944A/en unknown
- 2004-07-09 AT AT04741020T patent/ATE467638T1/en active
- 2004-07-09 US US10/564,325 patent/US7288536B2/en active Active
-
2005
- 2005-12-22 IL IL172776A patent/IL172776A/en active IP Right Grant
- 2005-12-22 IS IS8194A patent/IS2776B/en unknown
- 2005-12-22 IS IS8193A patent/IS2909B/en unknown
- 2005-12-22 IL IL172777A patent/IL172777A/en active IP Right Grant
-
2006
- 2006-01-06 NO NO20060111A patent/NO333263B1/en not_active IP Right Cessation
- 2006-01-06 MA MA28701A patent/MA27897A1/en unknown
- 2006-01-06 MA MA28703A patent/MA27899A1/en unknown
- 2006-01-06 NO NO20060110A patent/NO332041B1/en not_active IP Right Cessation
- 2006-01-10 ZA ZA200600226A patent/ZA200600226B/en unknown
- 2006-01-10 ZA ZA200600223A patent/ZA200600223B/en unknown
- 2006-08-29 HK HK06109622.1A patent/HK1089186A1/en not_active IP Right Cessation
- 2006-08-29 HK HK06109621.2A patent/HK1089185A1/en not_active IP Right Cessation
-
2007
- 2007-09-28 US US11/863,419 patent/US20080021231A1/en not_active Abandoned
- 2007-09-28 US US11/863,390 patent/US7638508B2/en active Active
- 2007-09-28 US US11/863,439 patent/US7524970B2/en active Active
-
2009
- 2009-04-03 RU RU2009112207/04A patent/RU2009112207A/en not_active Application Discontinuation
-
2010
- 2010-03-01 US US12/714,961 patent/US20100152148A1/en not_active Abandoned
- 2010-06-29 HR HR20100359T patent/HRP20100359T1/en unknown
- 2010-06-30 CY CY20101100601T patent/CY1110149T1/en unknown
- 2010-12-23 IL IL210209A patent/IL210209A0/en unknown
-
2011
- 2011-01-07 JP JP2011001699A patent/JP2011093929A/en active Pending
-
2013
- 2013-01-23 HR HRP20130056TT patent/HRP20130056T1/en unknown
- 2013-03-19 CY CY20131100230T patent/CY1113836T1/en unknown
-
2014
- 2014-10-28 IS IS050094A patent/IS2928B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110149T1 (en) | SPECIAL COMPONENT OF GLUCCORDOSTEROID WITH ANTI-INFLAMMATIVE ACTIVITY | |
ME01992B (en) | Diarylhydantoin compounds | |
CY1111671T1 (en) | Heterocyclic compound | |
UY28290A1 (en) | NEW PHARMACEUTICAL COMPOUNDS | |
EA200801381A1 (en) | DERIVATIVES OF PYRIMIDINE | |
CY1114083T1 (en) | COMBINATION OF A UNION OF 5-FENYLOTHIACEAOL AS A PIECE INHIBITOR WITH AN ANTI-INFLAMMATIVE, BRAINSTEADIC OR ANTI-ANTIQUE | |
CY1113657T1 (en) | NEW PRODUCERS OF BENZOFFAINE OR SALTS | |
DE60335359D1 (en) | phthalazinone | |
EA200700188A1 (en) | DERIVATIVES OF SUBSTITUTED 2-ALKYLKHINAZOLINON AS PARP INHIBITORS | |
ATE360627T1 (en) | PYRROLIDINDONE-SUBSTITUTED PIPERIDINE PHTHALAZONES AS PDE4 INHIBITORS | |
CY1112886T1 (en) | Immunosuppressive agent which includes a heterocyclic compound as an active ingredient | |
DE60230890D1 (en) | INDOLICINE AS KINASEPROTEINHEMMER | |
ATE403429T1 (en) | SPIROPYRAZOLE COMPOUNDS | |
CY1106247T1 (en) | THIOPHEN- AND THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | |
ATE553106T1 (en) | HETEROARYLPYRROLOPYRIDINONES AS KINASE INHIBITORS | |
ATE482932T1 (en) | N-ALKYNYL-2-(SUBSTITUTED ARYLOXY)ALKYLTHIOAMIDE DERIVATIVES AS FUNGICIDES | |
ATE335426T1 (en) | EXTENSION SET FOR DRAWERS | |
ECSP055863A (en) | PYRIDODIACINS AS FUNGUICIDES OF PLANTS | |
ITVR20020062A1 (en) | ESTEMPORANEOUS PREPARATION OF ORGANIC PERIOXYACIDS STABLE OVER TIME | |
EA200801596A1 (en) | NEW 11-BETA-HYDROXYANDROST-4-EN-3-ONE | |
HRP20080529T3 (en) | Amide prodrug of gemcitabine, compositions and use thereof | |
EA200700901A1 (en) | DERIVATIVES 2-AMIDO-4-PHENYL THIAZOLE, THEIR OBTAINING AND USE IN THERAPY | |
DE60319349D1 (en) | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC EFFECT | |
EA200970372A1 (en) | ALGHEIMER'S DISEASE INHIBITOR CONTAINING HETEROCYCLIC COMPOUND | |
EA200801366A1 (en) | DERIVATIVES 3,6-DIGIDRO-2-OXO-6N-1,3,4-TIADIAZINA |